CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.22 per share a year ago.